Biotech · Private company · San Francisco, CA, US
Exavir Therapeutics Inc.
Track this companyFree. Adds Exavir Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infectionFiscal year 2026 · $998KNIH RePORTER 1R44AI195119-01 · fetched Nov 12, 2026
- XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studiesFiscal year 2025 · $1MNIH RePORTER 5R44AI179564-03 · fetched Nov 12, 2026
- XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studiesFiscal year 2024 · $1MNIH RePORTER 5R44AI179564-02 · fetched Nov 12, 2026